搜索
Recursion Pharmaceuticals Inc
RXRX添加自选
3.050USD
-0.100-3.17%
收盘 05/13, 16:00（美东）报价延迟15分钟
1.67B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.17%
5天
-11.08%
1月
-10.82%
6月
-29.56%
今年开始到现在
-25.43%
1年
-32.37%
TradingKey Recursion Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-05-13操作建议
Recursion Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名138/383位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价6.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Recursion Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Recursion Pharmaceuticals Inc亮点
亮点风险
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
业绩高增长
公司营业收入稳步增长，连续3年增长67.54%
业绩增长期
公司处于发展阶段，最新年度总收入74.68M美元
利润高增长
公司净利润处于行业前列，最新年度总收入74.68M美元
估值高估
公司最新PE估值-2.63，处于3年历史高位
机构加仓
最新机构持股388.34M股，环比增加10.70%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值10.11K
分析师目标
根据
8
位分析师
持有
评级
6.000
目标均价
+84.05%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Recursion Pharmaceuticals Inc简介
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
公司代码RXRX
公司Recursion Pharmaceuticals Inc
CEOKhan (Najat)
网址https://www.recursion.com/
相关品种
